AKT1 and breast carcinoma: This high frequency is similar to that reported by comprehensive genomic profiling.7, 9, 11 Neither of the two currently approved drugs that inhibit the PI3K/AKT/PTEN pathway (the PI3K inhibitor alpelisib or mTORC1 inhibitor everolimus) added to endocrine therapy have been shown to significantly extend overall survival compared with endocrine therapy alone,13, 15 highlighting the need for new breast cancer therapies against the pathway.